Circulating tumor DNA-From bench to bedside.

View/ Open
Date
2017-05Author
Lim, JSJ
Janku, F
Yap, TA
Type
Journal Article
Metadata
Show full item recordAbstract
In the era of personalized medicine, tumor sampling is paramount to enable the assessment of actionable molecular aberrations to help rationalize and guide treatment decisions. Longitudinal tracking of such aberrations may also be helpful to detect emerging drug resistance and to allow for timely modifications to ongoing therapies to improve patient outcomes. Nevertheless, tumor tissue sampling involves an invasive procedure with potential risks to patients and involves logistical challenges. As such, other less invasive and safer methods such as blood sampling for molecular profiling has been gaining traction. In this article, we discuss the concept of circulating tumor DNA, the technology platforms available for its interrogation, and its current applications in the clinic. We also envision how circulating tumor DNA may be applied at multiple time points along a patient's cancer journey to guide diagnosis, prognostication, and therapeutic decisions.
Collections
Subject
Humans
Neoplasms
MicroRNAs
Antineoplastic Agents
Biopsy
Prognosis
Gene Expression Profiling
Polymerase Chain Reaction
Sequence Analysis, DNA
DNA Mutational Analysis
Mutation
United States Food and Drug Administration
United States
Early Detection of Cancer
Genetic Testing
High-Throughput Nucleotide Sequencing
Carcinogenesis
Biomarkers, Tumor
Precision Medicine
Circulating Tumor DNA
Research team
Medicine Drug Development Unit (de Bono)
Language
eng
License start date
2017-05
Citation
Current problems in cancer, 2017, 41 (3), pp. 212 - 221